Regen BioPharma, Inc. Begins Experiments Validating Its Proprietary CAR-T Cell Therapy

Company Engages Top-Tier Contract Research Organization SAN DIEGO, Sept. 13, 2022 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today initiation of a series of phased experiments to begin the process of moving its CAR-T cell de-differentiation…

Click here to view original post